153 related articles for article (PubMed ID: 33141360)
1. The role of MYB proto-oncogene like 2 in tamoxifen resistance in breast cancer.
Li X; Zhang X; Wu CC; Li PP; Fu YM; Xie LH; Sun SS; Zhou YY; Zhu BL
J Mol Histol; 2021 Feb; 52(1):21-30. PubMed ID: 33141360
[TBL] [Abstract][Full Text] [Related]
2. MYBL2 Is Targeted by miR-143-3p and Regulates Breast Cancer Cell Proliferation and Apoptosis.
Chen J; Chen X
Oncol Res; 2018 Jul; 26(6):913-922. PubMed ID: 29268817
[TBL] [Abstract][Full Text] [Related]
3. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
4. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
5. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH.
Xiong YC; Wang J; Cheng Y; Zhang XY; Ye XQ
Mol Cell Biochem; 2020 May; 468(1-2):185-193. PubMed ID: 32200471
[TBL] [Abstract][Full Text] [Related]
6. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells.
Li J; Chen H
Bioengineered; 2022 Apr; 13(4):9019-9031. PubMed ID: 35341461
[TBL] [Abstract][Full Text] [Related]
7. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
9. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
10. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
12. MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3.
Liu W; Shen D; Ju L; Zhang R; Du W; Jin W; Xiong K; Wang G; Qian K; Zhang Y; Xiao Y; Wang X
Oncogene; 2022 Oct; 41(41):4606-4617. PubMed ID: 36071275
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
14. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.
Zhang X; Lv QL; Huang YT; Zhang LH; Zhou HH
J Exp Clin Cancer Res; 2017 Aug; 36(1):105. PubMed ID: 28784180
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
Lee J; Jeong JH; Jung JH; Kim WW; Lee SJ; Park JY; Park JY; Kang SH; Kim EA; Park JH; Chae YS; Park HY
Oncology; 2019; 97(3):180-188. PubMed ID: 31330520
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial transcriptional regulation of HEB/ZEB1/ASCL1 and MYBL2 on Ras/ErbB signaling.
Zhong F; Chen T; Li B
Biochem Biophys Res Commun; 2022 Sep; 622():170-176. PubMed ID: 35932528
[TBL] [Abstract][Full Text] [Related]
17. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
18. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
19. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
20. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]